Atea Pharmaceuticals Inc. (AVIR): Price and Financial Metrics
AVIR Price/Volume Stats
| Current price | $4.50 | 52-week high | $9.79 |
| Prev. close | $4.08 | 52-week low | $2.94 |
| Day low | $4.10 | Volume | 1,290,900 |
| Day high | $4.52 | Avg. volume | 653,578 |
| 50-day MA | $3.55 | Dividend yield | N/A |
| 200-day MA | $4.77 | Market Cap | 375.30M |
AVIR Stock Price Chart Interactive Chart >
Atea Pharmaceuticals Inc. (AVIR) Company Bio
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Latest AVIR News From Around the Web
Below are the latest news stories about ATEA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AVIR as an investment opportunity.
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesProposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its ShareholdersBOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquir |
Lordstown Motors and Atea Pharmaceuticals Stock See Action From Activist InvestorsLordstown Motors’ former CEO Steve burns lowered his stake in the maker of electric trucks. Atea Pharmaceuticals is evaluating an M&A offer. |
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesBOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea’s programs. Atea’s Board of Directors and management team regularly re |
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call TranscriptAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript May 8, 2023 Atea Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.43, expectations were $-0.48. Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only […] |
Q1 2023 Atea Pharmaceuticals Inc Earnings CallQ1 2023 Atea Pharmaceuticals Inc Earnings Call |
AVIR Price Returns
| 1-mo | 34.33% |
| 3-mo | 34.73% |
| 6-mo | -3.43% |
| 1-year | -42.31% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -6.44% |
| 2022 | -46.20% |
| 2021 | -78.60% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...